Anti-influenza vaccination in systemic lupus erythematosus patients: an analysis of specific humoral response and vaccination safety
Identifieur interne : 001221 ( Istex/Corpus ); précédent : 001220; suivant : 001222Anti-influenza vaccination in systemic lupus erythematosus patients: an analysis of specific humoral response and vaccination safety
Auteurs : Ewa Wi Sik-Szewczyk ; Magdalena Romanowska ; Paweł Mielnik ; Hanna Chwali Ska-Sadowska ; Lidia B. Brydak ; Marzena Olesi Ska ; Jakub Z BekSource :
- Clinical Rheumatology [ 0770-3198 ] ; 2010-06-01.
English descriptors
Abstract
Abstract: The objective of this study is to evaluate efficacy and safety of influenza vaccine in systemic lupus erythematosus (SLE) patients. We studied SLE patients and healthy subjects immunised with inactivated influenza vaccine. Efficacy was measured by comparing humoral response to vaccine antigens between groups. Safety was monitored by SLEDAI and serological markers. Subjects attended visits at baseline and on post-vaccination weeks 4 and 12. We enrolled 62 SLE patients and 47 healthy subjects. In post-immunisation week 4, anti-haemagglutinin antibody titres rose in the patient group at least 6.23-fold, compared to 11.90-fold among controls (P ≤ 0.05). The seroconversion rate range was 53-56% among patients and 72-85% among controls (P < 0.05 for strains H1N1 and H3N2, NS for strain type B). The seroprotection rate ranged between 62% and 73% and between 90% and 98% in the patient and control group, respectively (P < 0.05). In post-vaccination week 12, the antibody titre was higher at least 3.86-fold in the patient group and 7.65-fold among controls. The seroconversion rate range was 32-40% among patients and 64-70% among controls, while the seroprotection rate ranged between 43% and 50% and between 79% and 94%, respectively (P < 0.005 for three strains). We identified one severe and six mild to moderate SLE exacerbations by week 12. The anti-nuclear antibodies and anti-double-stranded DNA titres grew by post-immunisation week 4 (P < 0.05). The post-vaccination response was weaker in SLE patients compared to healthy subjects. Immunisation did not change underlying disease activity.
Url:
DOI: 10.1007/s10067-010-1373-y
Links to Exploration step
ISTEX:1041971C4FEB9CD06B2A3612E04E92D8BD2C455FLe document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Anti-influenza vaccination in systemic lupus erythematosus patients: an analysis of specific humoral response and vaccination safety</title><author><name sortKey="Wi Sik Szewczyk, Ewa" sort="Wi Sik Szewczyk, Ewa" uniqKey="Wi Sik Szewczyk E" first="Ewa" last="Wi Sik-Szewczyk">Ewa Wi Sik-Szewczyk</name><affiliation><mods:affiliation>Department of Systemic Connective Tissue Diseases, Institute of Rheumatology, Spartanska 1, 02-637, Warsaw, Poland</mods:affiliation></affiliation><affiliation><mods:affiliation>E-mail: ewa.w.szewczyk@gmail.com</mods:affiliation></affiliation></author><author><name sortKey="Romanowska, Magdalena" sort="Romanowska, Magdalena" uniqKey="Romanowska M" first="Magdalena" last="Romanowska">Magdalena Romanowska</name><affiliation><mods:affiliation>National Influenza Center, National Institute of Public Health, National Institute of Hygiene, Warsaw, Poland</mods:affiliation></affiliation></author><author><name sortKey="Mielnik, Pawel" sort="Mielnik, Pawel" uniqKey="Mielnik P" first="Paweł" last="Mielnik">Paweł Mielnik</name><affiliation><mods:affiliation>Department of Systemic Connective Tissue Diseases, Institute of Rheumatology, Spartanska 1, 02-637, Warsaw, Poland</mods:affiliation></affiliation></author><author><name sortKey="Chwali Ska Sadowska, Hanna" sort="Chwali Ska Sadowska, Hanna" uniqKey="Chwali Ska Sadowska H" first="Hanna" last="Chwali Ska-Sadowska">Hanna Chwali Ska-Sadowska</name><affiliation><mods:affiliation>Department of Systemic Connective Tissue Diseases, Institute of Rheumatology, Spartanska 1, 02-637, Warsaw, Poland</mods:affiliation></affiliation></author><author><name sortKey="Brydak, Lidia B" sort="Brydak, Lidia B" uniqKey="Brydak L" first="Lidia B." last="Brydak">Lidia B. Brydak</name><affiliation><mods:affiliation>National Influenza Center, National Institute of Public Health, National Institute of Hygiene, Warsaw, Poland</mods:affiliation></affiliation></author><author><name sortKey="Olesi Ska, Marzena" sort="Olesi Ska, Marzena" uniqKey="Olesi Ska M" first="Marzena" last="Olesi Ska">Marzena Olesi Ska</name><affiliation><mods:affiliation>Department of Systemic Connective Tissue Diseases, Institute of Rheumatology, Spartanska 1, 02-637, Warsaw, Poland</mods:affiliation></affiliation></author><author><name sortKey="Z Bek, Jakub" sort="Z Bek, Jakub" uniqKey="Z Bek J" first="Jakub" last="Z Bek">Jakub Z Bek</name><affiliation><mods:affiliation>Department of Microbiology and Serology, Institute of Rheumatology, Warsaw, Poland</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:1041971C4FEB9CD06B2A3612E04E92D8BD2C455F</idno><date when="2010" year="2010">2010</date><idno type="doi">10.1007/s10067-010-1373-y</idno><idno type="url">https://api.istex.fr/ark:/67375/VQC-GHPFLTH2-4/fulltext.pdf</idno><idno type="wicri:Area/Istex/Corpus">001221</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">001221</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Anti-influenza vaccination in systemic lupus erythematosus patients: an analysis of specific humoral response and vaccination safety</title><author><name sortKey="Wi Sik Szewczyk, Ewa" sort="Wi Sik Szewczyk, Ewa" uniqKey="Wi Sik Szewczyk E" first="Ewa" last="Wi Sik-Szewczyk">Ewa Wi Sik-Szewczyk</name><affiliation><mods:affiliation>Department of Systemic Connective Tissue Diseases, Institute of Rheumatology, Spartanska 1, 02-637, Warsaw, Poland</mods:affiliation></affiliation><affiliation><mods:affiliation>E-mail: ewa.w.szewczyk@gmail.com</mods:affiliation></affiliation></author><author><name sortKey="Romanowska, Magdalena" sort="Romanowska, Magdalena" uniqKey="Romanowska M" first="Magdalena" last="Romanowska">Magdalena Romanowska</name><affiliation><mods:affiliation>National Influenza Center, National Institute of Public Health, National Institute of Hygiene, Warsaw, Poland</mods:affiliation></affiliation></author><author><name sortKey="Mielnik, Pawel" sort="Mielnik, Pawel" uniqKey="Mielnik P" first="Paweł" last="Mielnik">Paweł Mielnik</name><affiliation><mods:affiliation>Department of Systemic Connective Tissue Diseases, Institute of Rheumatology, Spartanska 1, 02-637, Warsaw, Poland</mods:affiliation></affiliation></author><author><name sortKey="Chwali Ska Sadowska, Hanna" sort="Chwali Ska Sadowska, Hanna" uniqKey="Chwali Ska Sadowska H" first="Hanna" last="Chwali Ska-Sadowska">Hanna Chwali Ska-Sadowska</name><affiliation><mods:affiliation>Department of Systemic Connective Tissue Diseases, Institute of Rheumatology, Spartanska 1, 02-637, Warsaw, Poland</mods:affiliation></affiliation></author><author><name sortKey="Brydak, Lidia B" sort="Brydak, Lidia B" uniqKey="Brydak L" first="Lidia B." last="Brydak">Lidia B. Brydak</name><affiliation><mods:affiliation>National Influenza Center, National Institute of Public Health, National Institute of Hygiene, Warsaw, Poland</mods:affiliation></affiliation></author><author><name sortKey="Olesi Ska, Marzena" sort="Olesi Ska, Marzena" uniqKey="Olesi Ska M" first="Marzena" last="Olesi Ska">Marzena Olesi Ska</name><affiliation><mods:affiliation>Department of Systemic Connective Tissue Diseases, Institute of Rheumatology, Spartanska 1, 02-637, Warsaw, Poland</mods:affiliation></affiliation></author><author><name sortKey="Z Bek, Jakub" sort="Z Bek, Jakub" uniqKey="Z Bek J" first="Jakub" last="Z Bek">Jakub Z Bek</name><affiliation><mods:affiliation>Department of Microbiology and Serology, Institute of Rheumatology, Warsaw, Poland</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">Clinical Rheumatology</title><title level="j" type="sub">Journal of the International League of Associations for Rheumatology</title><title level="j" type="abbrev">Clin Rheumatol</title><idno type="ISSN">0770-3198</idno><idno type="eISSN">1434-9949</idno><imprint><publisher>Springer-Verlag</publisher><pubPlace>London</pubPlace><date type="published" when="2010-06-01">2010-06-01</date><biblScope unit="volume">29</biblScope><biblScope unit="issue">6</biblScope><biblScope unit="page" from="605">605</biblScope><biblScope unit="page" to="613">613</biblScope></imprint><idno type="ISSN">0770-3198</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0770-3198</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Humoral response</term><term>Influenza vaccination</term><term>Lupus erythematosus</term><term>Safety</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Abstract: The objective of this study is to evaluate efficacy and safety of influenza vaccine in systemic lupus erythematosus (SLE) patients. We studied SLE patients and healthy subjects immunised with inactivated influenza vaccine. Efficacy was measured by comparing humoral response to vaccine antigens between groups. Safety was monitored by SLEDAI and serological markers. Subjects attended visits at baseline and on post-vaccination weeks 4 and 12. We enrolled 62 SLE patients and 47 healthy subjects. In post-immunisation week 4, anti-haemagglutinin antibody titres rose in the patient group at least 6.23-fold, compared to 11.90-fold among controls (P ≤ 0.05). The seroconversion rate range was 53-56% among patients and 72-85% among controls (P < 0.05 for strains H1N1 and H3N2, NS for strain type B). The seroprotection rate ranged between 62% and 73% and between 90% and 98% in the patient and control group, respectively (P < 0.05). In post-vaccination week 12, the antibody titre was higher at least 3.86-fold in the patient group and 7.65-fold among controls. The seroconversion rate range was 32-40% among patients and 64-70% among controls, while the seroprotection rate ranged between 43% and 50% and between 79% and 94%, respectively (P < 0.005 for three strains). We identified one severe and six mild to moderate SLE exacerbations by week 12. The anti-nuclear antibodies and anti-double-stranded DNA titres grew by post-immunisation week 4 (P < 0.05). The post-vaccination response was weaker in SLE patients compared to healthy subjects. Immunisation did not change underlying disease activity.</div></front></TEI><istex><corpusName>springer-journals</corpusName><author><json:item><name>Ewa Więsik-Szewczyk</name><affiliations><json:string>Department of Systemic Connective Tissue Diseases, Institute of Rheumatology, Spartanska 1, 02-637, Warsaw, Poland</json:string><json:string>E-mail: ewa.w.szewczyk@gmail.com</json:string></affiliations></json:item><json:item><name>Magdalena Romanowska</name><affiliations><json:string>National Influenza Center, National Institute of Public Health, National Institute of Hygiene, Warsaw, Poland</json:string></affiliations></json:item><json:item><name>Paweł Mielnik</name><affiliations><json:string>Department of Systemic Connective Tissue Diseases, Institute of Rheumatology, Spartanska 1, 02-637, Warsaw, Poland</json:string></affiliations></json:item><json:item><name>Hanna Chwalińska-Sadowska</name><affiliations><json:string>Department of Systemic Connective Tissue Diseases, Institute of Rheumatology, Spartanska 1, 02-637, Warsaw, Poland</json:string></affiliations></json:item><json:item><name>Lidia B. Brydak</name><affiliations><json:string>National Influenza Center, National Institute of Public Health, National Institute of Hygiene, Warsaw, Poland</json:string></affiliations></json:item><json:item><name>Marzena Olesińska</name><affiliations><json:string>Department of Systemic Connective Tissue Diseases, Institute of Rheumatology, Spartanska 1, 02-637, Warsaw, Poland</json:string></affiliations></json:item><json:item><name>Jakub Ząbek</name><affiliations><json:string>Department of Microbiology and Serology, Institute of Rheumatology, Warsaw, Poland</json:string></affiliations></json:item></author><subject><json:item><lang><json:string>eng</json:string></lang><value>Humoral response</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>Influenza vaccination</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>Lupus erythematosus</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>Safety</value></json:item></subject><articleId><json:string>1373</json:string><json:string>s10067-010-1373-y</json:string></articleId><arkIstex>ark:/67375/VQC-GHPFLTH2-4</arkIstex><language><json:string>eng</json:string></language><originalGenre><json:string>OriginalPaper</json:string></originalGenre><abstract>Abstract: The objective of this study is to evaluate efficacy and safety of influenza vaccine in systemic lupus erythematosus (SLE) patients. We studied SLE patients and healthy subjects immunised with inactivated influenza vaccine. Efficacy was measured by comparing humoral response to vaccine antigens between groups. Safety was monitored by SLEDAI and serological markers. Subjects attended visits at baseline and on post-vaccination weeks 4 and 12. We enrolled 62 SLE patients and 47 healthy subjects. In post-immunisation week 4, anti-haemagglutinin antibody titres rose in the patient group at least 6.23-fold, compared to 11.90-fold among controls (P ≤ 0.05). The seroconversion rate range was 53-56% among patients and 72-85% among controls (P > 0.05 for strains H1N1 and H3N2, NS for strain type B). The seroprotection rate ranged between 62% and 73% and between 90% and 98% in the patient and control group, respectively (P > 0.05). In post-vaccination week 12, the antibody titre was higher at least 3.86-fold in the patient group and 7.65-fold among controls. The seroconversion rate range was 32-40% among patients and 64-70% among controls, while the seroprotection rate ranged between 43% and 50% and between 79% and 94%, respectively (P > 0.005 for three strains). We identified one severe and six mild to moderate SLE exacerbations by week 12. The anti-nuclear antibodies and anti-double-stranded DNA titres grew by post-immunisation week 4 (P > 0.05). The post-vaccination response was weaker in SLE patients compared to healthy subjects. Immunisation did not change underlying disease activity.</abstract><qualityIndicators><score>9.418</score><pdfWordCount>4586</pdfWordCount><pdfCharCount>30248</pdfCharCount><pdfVersion>1.3</pdfVersion><pdfPageCount>9</pdfPageCount><pdfPageSize>595.276 x 790.866 pts</pdfPageSize><refBibsNative>false</refBibsNative><abstractWordCount>236</abstractWordCount><abstractCharCount>1614</abstractCharCount><keywordCount>4</keywordCount></qualityIndicators><title>Anti-influenza vaccination in systemic lupus erythematosus patients: an analysis of specific humoral response and vaccination safety</title><genre><json:string>research-article</json:string></genre><host><title>Clinical Rheumatology</title><language><json:string>unknown</json:string></language><publicationDate>2010</publicationDate><copyrightDate>2010</copyrightDate><issn><json:string>0770-3198</json:string></issn><eissn><json:string>1434-9949</json:string></eissn><journalId><json:string>10067</json:string></journalId><volume>29</volume><issue>6</issue><pages><first>605</first><last>613</last></pages><genre><json:string>journal</json:string></genre><subject><json:item><value>Rheumatology</value></json:item></subject></host><ark><json:string>ark:/67375/VQC-GHPFLTH2-4</json:string></ark><publicationDate>2010</publicationDate><copyrightDate>2010</copyrightDate><doi><json:string>10.1007/s10067-010-1373-y</json:string></doi><id>1041971C4FEB9CD06B2A3612E04E92D8BD2C455F</id><score>1</score><fulltext><json:item><extension>pdf</extension><original>true</original><mimetype>application/pdf</mimetype><uri>https://api.istex.fr/ark:/67375/VQC-GHPFLTH2-4/fulltext.pdf</uri></json:item><json:item><extension>zip</extension><original>false</original><mimetype>application/zip</mimetype><uri>https://api.istex.fr/ark:/67375/VQC-GHPFLTH2-4/bundle.zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/ark:/67375/VQC-GHPFLTH2-4/fulltext.tei"><teiHeader><fileDesc><titleStmt><title level="a" type="main" xml:lang="en">Anti-influenza vaccination in systemic lupus erythematosus patients: an analysis of specific humoral response and vaccination safety</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher scheme="https://scientific-publisher.data.istex.fr">Springer-Verlag</publisher><pubPlace>London</pubPlace><availability><licence><p>Clinical Rheumatology, 2010</p></licence><p scheme="https://loaded-corpus.data.istex.fr/ark:/67375/XBH-3XSW68JL-F">springer</p></availability><date>2009-11-10</date></publicationStmt><notesStmt><note type="research-article" scheme="https://content-type.data.istex.fr/ark:/67375/XTP-1JC4F85T-7">research-article</note><note type="journal" scheme="https://publication-type.data.istex.fr/ark:/67375/JMC-0GLKJH51-B">journal</note><note>Original Article</note></notesStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a" type="main" xml:lang="en">Anti-influenza vaccination in systemic lupus erythematosus patients: an analysis of specific humoral response and vaccination safety</title><author xml:id="author-0000" corresp="yes"><persName><forename type="first">Ewa</forename><surname>Więsik-Szewczyk</surname></persName><email>ewa.w.szewczyk@gmail.com</email><affiliation>Department of Systemic Connective Tissue Diseases, Institute of Rheumatology, Spartanska 1, 02-637, Warsaw, Poland</affiliation></author><author xml:id="author-0001"><persName><forename type="first">Magdalena</forename><surname>Romanowska</surname></persName><affiliation>National Influenza Center, National Institute of Public Health, National Institute of Hygiene, Warsaw, Poland</affiliation></author><author xml:id="author-0002"><persName><forename type="first">Paweł</forename><surname>Mielnik</surname></persName><affiliation>Department of Systemic Connective Tissue Diseases, Institute of Rheumatology, Spartanska 1, 02-637, Warsaw, Poland</affiliation></author><author xml:id="author-0003"><persName><forename type="first">Hanna</forename><surname>Chwalińska-Sadowska</surname></persName><affiliation>Department of Systemic Connective Tissue Diseases, Institute of Rheumatology, Spartanska 1, 02-637, Warsaw, Poland</affiliation></author><author xml:id="author-0004"><persName><forename type="first">Lidia</forename><surname>Brydak</surname></persName><affiliation>National Influenza Center, National Institute of Public Health, National Institute of Hygiene, Warsaw, Poland</affiliation></author><author xml:id="author-0005"><persName><forename type="first">Marzena</forename><surname>Olesińska</surname></persName><affiliation>Department of Systemic Connective Tissue Diseases, Institute of Rheumatology, Spartanska 1, 02-637, Warsaw, Poland</affiliation></author><author xml:id="author-0006"><persName><forename type="first">Jakub</forename><surname>Ząbek</surname></persName><affiliation>Department of Microbiology and Serology, Institute of Rheumatology, Warsaw, Poland</affiliation></author><idno type="istex">1041971C4FEB9CD06B2A3612E04E92D8BD2C455F</idno><idno type="ark">ark:/67375/VQC-GHPFLTH2-4</idno><idno type="DOI">10.1007/s10067-010-1373-y</idno><idno type="article-id">1373</idno><idno type="article-id">s10067-010-1373-y</idno></analytic><monogr><title level="j">Clinical Rheumatology</title><title level="j" type="sub">Journal of the International League of Associations for Rheumatology</title><title level="j" type="abbrev">Clin Rheumatol</title><idno type="pISSN">0770-3198</idno><idno type="eISSN">1434-9949</idno><idno type="journal-ID">true</idno><idno type="issue-article-count">18</idno><idno type="volume-issue-count">12</idno><imprint><publisher>Springer-Verlag</publisher><pubPlace>London</pubPlace><date type="published" when="2010-06-01"></date><biblScope unit="volume">29</biblScope><biblScope unit="issue">6</biblScope><biblScope unit="page" from="605">605</biblScope><biblScope unit="page" to="613">613</biblScope></imprint></monogr></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>2009-11-10</date></creation><langUsage><language ident="en">en</language></langUsage><abstract xml:lang="en"><p>Abstract: The objective of this study is to evaluate efficacy and safety of influenza vaccine in systemic lupus erythematosus (SLE) patients. We studied SLE patients and healthy subjects immunised with inactivated influenza vaccine. Efficacy was measured by comparing humoral response to vaccine antigens between groups. Safety was monitored by SLEDAI and serological markers. Subjects attended visits at baseline and on post-vaccination weeks 4 and 12. We enrolled 62 SLE patients and 47 healthy subjects. In post-immunisation week 4, anti-haemagglutinin antibody titres rose in the patient group at least 6.23-fold, compared to 11.90-fold among controls (P ≤ 0.05). The seroconversion rate range was 53-56% among patients and 72-85% among controls (P < 0.05 for strains H1N1 and H3N2, NS for strain type B). The seroprotection rate ranged between 62% and 73% and between 90% and 98% in the patient and control group, respectively (P < 0.05). In post-vaccination week 12, the antibody titre was higher at least 3.86-fold in the patient group and 7.65-fold among controls. The seroconversion rate range was 32-40% among patients and 64-70% among controls, while the seroprotection rate ranged between 43% and 50% and between 79% and 94%, respectively (P < 0.005 for three strains). We identified one severe and six mild to moderate SLE exacerbations by week 12. The anti-nuclear antibodies and anti-double-stranded DNA titres grew by post-immunisation week 4 (P < 0.05). The post-vaccination response was weaker in SLE patients compared to healthy subjects. Immunisation did not change underlying disease activity.</p></abstract><textClass xml:lang="en"><keywords scheme="keyword"><list><head>Keywords</head><item><term>Humoral response</term></item><item><term>Influenza vaccination</term></item><item><term>Lupus erythematosus</term></item><item><term>Safety</term></item></list></keywords></textClass><textClass><keywords scheme="Journal Subject"><list><head>Medicine & Public Health</head><item><term>Rheumatology</term></item></list></keywords></textClass></profileDesc><revisionDesc><change when="2009-11-10">Created</change><change when="2010-06-01">Published</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><extension>txt</extension><original>false</original><mimetype>text/plain</mimetype><uri>https://api.istex.fr/ark:/67375/VQC-GHPFLTH2-4/fulltext.txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="corpus springer-journals not found" wicri:toSee="no header"><istex:xmlDeclaration>version="1.0" encoding="UTF-8"</istex:xmlDeclaration><istex:docType PUBLIC="-//Springer-Verlag//DTD A++ V2.4//EN" URI="http://devel.springer.de/A++/V2.4/DTD/A++V2.4.dtd" name="istex:docType"></istex:docType><istex:document><Publisher><PublisherInfo><PublisherName>Springer-Verlag</PublisherName><PublisherLocation>London</PublisherLocation></PublisherInfo><Journal OutputMedium="All"><JournalInfo JournalProductType="ArchiveJournal" NumberingStyle="Unnumbered"><JournalID>10067</JournalID><JournalPrintISSN>0770-3198</JournalPrintISSN><JournalElectronicISSN>1434-9949</JournalElectronicISSN><JournalTitle>Clinical Rheumatology</JournalTitle><JournalSubTitle>Journal of the International League of Associations for Rheumatology</JournalSubTitle><JournalAbbreviatedTitle>Clin Rheumatol</JournalAbbreviatedTitle><JournalSubjectGroup><JournalSubject Type="Primary">Medicine & Public Health</JournalSubject><JournalSubject Type="Secondary">Rheumatology </JournalSubject></JournalSubjectGroup></JournalInfo><Volume OutputMedium="All"><VolumeInfo TocLevels="0" VolumeType="Regular"><VolumeIDStart>29</VolumeIDStart><VolumeIDEnd>29</VolumeIDEnd><VolumeIssueCount>12</VolumeIssueCount></VolumeInfo><Issue IssueType="Regular" OutputMedium="All"><IssueInfo IssueType="Regular" TocLevels="0"><IssueIDStart>6</IssueIDStart><IssueIDEnd>6</IssueIDEnd><IssueArticleCount>18</IssueArticleCount><IssueHistory><OnlineDate><Year>2010</Year><Month>4</Month><Day>27</Day></OnlineDate><PrintDate><Year>2010</Year><Month>4</Month><Day>26</Day></PrintDate><CoverDate><Year>2010</Year><Month>6</Month></CoverDate><PricelistYear>2010</PricelistYear></IssueHistory><IssueCopyright><CopyrightHolderName>Clinical Rheumatology</CopyrightHolderName><CopyrightYear>2010</CopyrightYear></IssueCopyright></IssueInfo><Article ID="s10067-010-1373-y" OutputMedium="All"><ArticleInfo ArticleType="OriginalPaper" ContainsESM="No" Language="En" NumberingStyle="Unnumbered" TocLevels="0"><ArticleID>1373</ArticleID><ArticleDOI>10.1007/s10067-010-1373-y</ArticleDOI><ArticleSequenceNumber>5</ArticleSequenceNumber><ArticleTitle Language="En">Anti-influenza vaccination in systemic lupus erythematosus patients: an analysis of specific humoral response and vaccination safety</ArticleTitle><ArticleCategory>Original Article</ArticleCategory><ArticleFirstPage>605</ArticleFirstPage><ArticleLastPage>613</ArticleLastPage><ArticleHistory><RegistrationDate><Year>2010</Year><Month>1</Month><Day>5</Day></RegistrationDate><Received><Year>2009</Year><Month>11</Month><Day>10</Day></Received><Accepted><Year>2010</Year><Month>1</Month><Day>4</Day></Accepted><OnlineDate><Year>2010</Year><Month>2</Month><Day>7</Day></OnlineDate></ArticleHistory><ArticleCopyright><CopyrightHolderName>Clinical Rheumatology</CopyrightHolderName><CopyrightYear>2010</CopyrightYear></ArticleCopyright><ArticleGrants Type="Regular"><MetadataGrant Grant="OpenAccess"></MetadataGrant><AbstractGrant Grant="OpenAccess"></AbstractGrant><BodyPDFGrant Grant="Restricted"></BodyPDFGrant><BodyHTMLGrant Grant="Restricted"></BodyHTMLGrant><BibliographyGrant Grant="Restricted"></BibliographyGrant><ESMGrant Grant="Restricted"></ESMGrant></ArticleGrants></ArticleInfo><ArticleHeader><AuthorGroup><Author AffiliationIDS="Aff1" CorrespondingAffiliationID="Aff1"><AuthorName DisplayOrder="Western"><GivenName>Ewa</GivenName><FamilyName>Więsik-Szewczyk</FamilyName></AuthorName><Contact><Phone>+48-22-8445726</Phone><Fax>+48-22-6467894</Fax><Email>ewa.w.szewczyk@gmail.com</Email></Contact></Author><Author AffiliationIDS="Aff2"><AuthorName DisplayOrder="Western"><GivenName>Magdalena</GivenName><FamilyName>Romanowska</FamilyName></AuthorName></Author><Author AffiliationIDS="Aff1"><AuthorName DisplayOrder="Western"><GivenName>Paweł</GivenName><FamilyName>Mielnik</FamilyName></AuthorName></Author><Author AffiliationIDS="Aff1"><AuthorName DisplayOrder="Western"><GivenName>Hanna</GivenName><FamilyName>Chwalińska-Sadowska</FamilyName></AuthorName></Author><Author AffiliationIDS="Aff2"><AuthorName DisplayOrder="Western"><GivenName>Lidia</GivenName><GivenName>B.</GivenName><FamilyName>Brydak</FamilyName></AuthorName></Author><Author AffiliationIDS="Aff1"><AuthorName DisplayOrder="Western"><GivenName>Marzena</GivenName><FamilyName>Olesińska</FamilyName></AuthorName></Author><Author AffiliationIDS="Aff3"><AuthorName DisplayOrder="Western"><GivenName>Jakub</GivenName><FamilyName>Ząbek</FamilyName></AuthorName></Author><Affiliation ID="Aff1"><OrgDivision>Department of Systemic Connective Tissue Diseases</OrgDivision><OrgName>Institute of Rheumatology</OrgName><OrgAddress><Street>Spartanska 1</Street><Postcode>02-637</Postcode><City>Warsaw</City><Country Code="PL">Poland</Country></OrgAddress></Affiliation><Affiliation ID="Aff2"><OrgDivision>National Influenza Center</OrgDivision><OrgName>National Institute of Public Health, National Institute of Hygiene</OrgName><OrgAddress><City>Warsaw</City><Country Code="PL">Poland</Country></OrgAddress></Affiliation><Affiliation ID="Aff3"><OrgDivision>Department of Microbiology and Serology</OrgDivision><OrgName>Institute of Rheumatology</OrgName><OrgAddress><City>Warsaw</City><Country Code="PL">Poland</Country></OrgAddress></Affiliation></AuthorGroup><Abstract ID="Abs1" Language="En" OutputMedium="All"><Heading>Abstract</Heading><Para>The objective of this study is to evaluate efficacy and safety of influenza vaccine in systemic lupus erythematosus (SLE) patients. We studied SLE patients and healthy subjects immunised with inactivated influenza vaccine. Efficacy was measured by comparing humoral response to vaccine antigens between groups. Safety was monitored by SLEDAI and serological markers. Subjects attended visits at baseline and on post-vaccination weeks 4 and 12. We enrolled 62 SLE patients and 47 healthy subjects. In post-immunisation week 4, anti-haemagglutinin antibody titres rose in the patient group at least 6.23-fold, compared to 11.90-fold among controls (<Emphasis Type="Italic">P</Emphasis> ≤ 0.05). The seroconversion rate range was 53-56% among patients and 72-85% among controls (<Emphasis Type="Italic">P</Emphasis> < 0.05 for strains H1N1 and H3N2, NS for strain type B). The seroprotection rate ranged between 62% and 73% and between 90% and 98% in the patient and control group, respectively (<Emphasis Type="Italic">P</Emphasis> < 0.05). In post-vaccination week 12, the antibody titre was higher at least 3.86-fold in the patient group and 7.65-fold among controls. The seroconversion rate range was 32-40% among patients and 64-70% among controls, while the seroprotection rate ranged between 43% and 50% and between 79% and 94%, respectively (<Emphasis Type="Italic">P</Emphasis> < 0.005 for three strains). We identified one severe and six mild to moderate SLE exacerbations by week 12. The anti-nuclear antibodies and anti-double-stranded DNA titres grew by post-immunisation week 4 (<Emphasis Type="Italic">P</Emphasis> < 0.05). The post-vaccination response was weaker in SLE patients compared to healthy subjects. Immunisation did not change underlying disease activity.</Para></Abstract><KeywordGroup Language="En" OutputMedium="All"><Heading>Keywords</Heading><Keyword>Humoral response</Keyword><Keyword>Influenza vaccination</Keyword><Keyword>Lupus erythematosus</Keyword><Keyword>Safety</Keyword></KeywordGroup></ArticleHeader><NoBody></NoBody></Article></Issue></Volume></Journal></Publisher></istex:document></istex:metadataXml><mods version="3.6"><titleInfo lang="en"><title>Anti-influenza vaccination in systemic lupus erythematosus patients: an analysis of specific humoral response and vaccination safety</title></titleInfo><titleInfo type="alternative" contentType="CDATA"><title>Anti-influenza vaccination in systemic lupus erythematosus patients: an analysis of specific humoral response and vaccination safety</title></titleInfo><name type="personal" displayLabel="corresp"><namePart type="given">Ewa</namePart><namePart type="family">Więsik-Szewczyk</namePart><affiliation>Department of Systemic Connective Tissue Diseases, Institute of Rheumatology, Spartanska 1, 02-637, Warsaw, Poland</affiliation><affiliation>E-mail: ewa.w.szewczyk@gmail.com</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Magdalena</namePart><namePart type="family">Romanowska</namePart><affiliation>National Influenza Center, National Institute of Public Health, National Institute of Hygiene, Warsaw, Poland</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Paweł</namePart><namePart type="family">Mielnik</namePart><affiliation>Department of Systemic Connective Tissue Diseases, Institute of Rheumatology, Spartanska 1, 02-637, Warsaw, Poland</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Hanna</namePart><namePart type="family">Chwalińska-Sadowska</namePart><affiliation>Department of Systemic Connective Tissue Diseases, Institute of Rheumatology, Spartanska 1, 02-637, Warsaw, Poland</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Lidia</namePart><namePart type="given">B.</namePart><namePart type="family">Brydak</namePart><affiliation>National Influenza Center, National Institute of Public Health, National Institute of Hygiene, Warsaw, Poland</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Marzena</namePart><namePart type="family">Olesińska</namePart><affiliation>Department of Systemic Connective Tissue Diseases, Institute of Rheumatology, Spartanska 1, 02-637, Warsaw, Poland</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Jakub</namePart><namePart type="family">Ząbek</namePart><affiliation>Department of Microbiology and Serology, Institute of Rheumatology, Warsaw, Poland</affiliation><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre type="research-article" displayLabel="OriginalPaper" authority="ISTEX" authorityURI="https://content-type.data.istex.fr" valueURI="https://content-type.data.istex.fr/ark:/67375/XTP-1JC4F85T-7">research-article</genre><originInfo><publisher>Springer-Verlag</publisher><place><placeTerm type="text">London</placeTerm></place><dateCreated encoding="w3cdtf">2009-11-10</dateCreated><dateIssued encoding="w3cdtf">2010-06-01</dateIssued><copyrightDate encoding="w3cdtf">2010</copyrightDate></originInfo><language><languageTerm type="code" authority="rfc3066">en</languageTerm><languageTerm type="code" authority="iso639-2b">eng</languageTerm></language><abstract lang="en">Abstract: The objective of this study is to evaluate efficacy and safety of influenza vaccine in systemic lupus erythematosus (SLE) patients. We studied SLE patients and healthy subjects immunised with inactivated influenza vaccine. Efficacy was measured by comparing humoral response to vaccine antigens between groups. Safety was monitored by SLEDAI and serological markers. Subjects attended visits at baseline and on post-vaccination weeks 4 and 12. We enrolled 62 SLE patients and 47 healthy subjects. In post-immunisation week 4, anti-haemagglutinin antibody titres rose in the patient group at least 6.23-fold, compared to 11.90-fold among controls (P ≤ 0.05). The seroconversion rate range was 53-56% among patients and 72-85% among controls (P < 0.05 for strains H1N1 and H3N2, NS for strain type B). The seroprotection rate ranged between 62% and 73% and between 90% and 98% in the patient and control group, respectively (P < 0.05). In post-vaccination week 12, the antibody titre was higher at least 3.86-fold in the patient group and 7.65-fold among controls. The seroconversion rate range was 32-40% among patients and 64-70% among controls, while the seroprotection rate ranged between 43% and 50% and between 79% and 94%, respectively (P < 0.005 for three strains). We identified one severe and six mild to moderate SLE exacerbations by week 12. The anti-nuclear antibodies and anti-double-stranded DNA titres grew by post-immunisation week 4 (P < 0.05). The post-vaccination response was weaker in SLE patients compared to healthy subjects. Immunisation did not change underlying disease activity.</abstract><note>Original Article</note><subject lang="en"><genre>Keywords</genre><topic>Humoral response</topic><topic>Influenza vaccination</topic><topic>Lupus erythematosus</topic><topic>Safety</topic></subject><relatedItem type="host"><titleInfo><title>Clinical Rheumatology</title><subTitle>Journal of the International League of Associations for Rheumatology</subTitle></titleInfo><titleInfo type="abbreviated"><title>Clin Rheumatol</title></titleInfo><genre type="journal" authority="ISTEX" authorityURI="https://publication-type.data.istex.fr" valueURI="https://publication-type.data.istex.fr/ark:/67375/JMC-0GLKJH51-B">journal</genre><originInfo><publisher>Springer</publisher><dateIssued encoding="w3cdtf">2010-04-27</dateIssued><copyrightDate encoding="w3cdtf">2010</copyrightDate></originInfo><subject><genre>Medicine & Public Health</genre><topic>Rheumatology</topic></subject><identifier type="ISSN">0770-3198</identifier><identifier type="eISSN">1434-9949</identifier><identifier type="JournalID">10067</identifier><identifier type="IssueArticleCount">18</identifier><identifier type="VolumeIssueCount">12</identifier><part><date>2010</date><detail type="volume"><number>29</number><caption>vol.</caption></detail><detail type="issue"><number>6</number><caption>no.</caption></detail><extent unit="pages"><start>605</start><end>613</end></extent></part><recordInfo><recordOrigin>Clinical Rheumatology, 2010</recordOrigin></recordInfo></relatedItem><identifier type="istex">1041971C4FEB9CD06B2A3612E04E92D8BD2C455F</identifier><identifier type="ark">ark:/67375/VQC-GHPFLTH2-4</identifier><identifier type="DOI">10.1007/s10067-010-1373-y</identifier><identifier type="ArticleID">1373</identifier><identifier type="ArticleID">s10067-010-1373-y</identifier><accessCondition type="use and reproduction" contentType="copyright">Clinical Rheumatology, 2010</accessCondition><recordInfo><recordContentSource authority="ISTEX" authorityURI="https://loaded-corpus.data.istex.fr" valueURI="https://loaded-corpus.data.istex.fr/ark:/67375/XBH-3XSW68JL-F">springer</recordContentSource><recordOrigin>Clinical Rheumatology, 2010</recordOrigin></recordInfo></mods><json:item><extension>json</extension><original>false</original><mimetype>application/json</mimetype><uri>https://api.istex.fr/ark:/67375/VQC-GHPFLTH2-4/record.json</uri></json:item></metadata><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/H2N2V1/Data/Istex/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001221 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Corpus/biblio.hfd -nk 001221 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= H2N2V1
|flux= Istex
|étape= Corpus
|type= RBID
|clé= ISTEX:1041971C4FEB9CD06B2A3612E04E92D8BD2C455F
|texte= Anti-influenza vaccination in systemic lupus erythematosus patients: an analysis of specific humoral response and vaccination safety
}}
| This area was generated with Dilib version V0.6.33. |  |